|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To achieve so, we used our recently developed mouse model, in which colon cancer arises in the absence of urokinase-type plasminogen activator (uPA) due to colitis induced by dextran sodium sulfate (DSS) treatment.
|
31758376 |
2020 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study shows that glucocorticoids reduced prostanoids, urokinase-type plasminogen activator (uPA) and angiopoietin-like protein-2 (ANGPTL2) levels, but increased angiogenin (ANG) in supernatant from human CT5.3hTERT colon cancer-derived myofibroblasts.
|
27717848 |
2017 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High tumor tissue expression of uPA and uPAR is associated with poor prognosis in lung, breast, and colon cancer patients in clinical studies.
|
26040548 |
2015 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
|
25113506 |
2014 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of the genes significantly affected in HCT-116 cells exposed to the ethanol extract at 3200 µg/ml, changes in expression of MYC, PLAU, and TEK may benefit the treatment of colon cancer.
|
23553997 |
2014 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of uPA and PAI-1 was increased in colon carcinoma cell lines when cultivated at pH 6.1, a value corresponding to intraabdominal pH values during CO(2) insufflation.
|
20931209 |
2011 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression.
|
16912170 |
2006 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because beta-catenin and its target genes urokinase-type plasminogen activator receptor (uPAR) and cyclin D1 are overexpressed in colon cancers, and are linked to cancer growth, invasion, and metastasis, we investigated whether DCA activates beta-catenin signaling and promotes colon cancer cell growth and invasiveness.
|
15004225 |
2004 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of urokinase-type plasminogen activator receptor (uPAR) in human colon cancer metastasis has not been tested using an antisense approach.
|
11291054 |
2001 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amiloride profoundly inhibited uPA mRNA production at concentrations between 0.1-1 mM in the presence or absence of PMA or CHX. uPA protein levels on the colon cancer cell surface reflected PMA induction and amiloride inhibition of uPA mRNA levels.
|
7750207 |
1995 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the localization of urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitors (PAI-1 and PAI-2) and plasminogen (plg) in 26 cases of colon cancer by immunohistochemical staining.
|
7737909 |
1995 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The colocalization of laminin-5 and urokinase-type plasminogen activator receptor in a subset of cancer cells in colon cancer also suggests that a controlled up-regulation of a number of gene products is a characteristic of budding colon cancer cells, and that these gene products serve functions crucial for the invasive phenotype of these cancer cells.
|
7664291 |
1995 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together with previous findings of urokinase-type plasminogen activator and its mRNA being located in fibroblast-like cells in the tumor stroma and mRNA for the urokinase receptor in the cancer cells at invasive foci, these results indicate a complex cooperativity among several cell types in regulation of plasminogen activation in colon cancer.
|
1855221 |
1991 |